ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1504

A Possible Contribution of Visfatin to the Resolution of Skin Sclerosis in Patients with Diffuse Cutaneous Systemic Sclerosis Via a Direct Anti-Fibrotic Effect On Dermal Fibroblasts and Th1 Polarization of the Immune Response

Tetsuo Toyama1, Yoshihide Asano2, Yuri Masui3, Sayaka Shibata2, Kaname Akamata1, Shinji Noda2, Naohiko Aozasa1, Takashi Taniguchi2, Takehiro Takahashi2, Yohei Ichimura2, Hayakazu Sumida2, Koichi Yanaba2, Takafumi Kadono2 and Shinichi Sato1, 1Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 3Department of Dermatology, University of Tokyo, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adipocytokines and systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Our latest studies have demonstrated that adipocytokines, including adiponectin, apelin, and retinol-binding protein-4, are potentially involved in the development of complicated clinical symptoms associated with systemic sclerosis (SSc). Visfatin is another member of adipocytokines with pro-fibrotic, pro-inflammatory, and immunomodulating properties, having been implicated in the pathogenesis of certain fibrotic and inflammatory autoimmune diseases. As an initial step of a series of studies regarding the role of vistatin in the pathogenesis of SSc, we herein investigated the clinical significance of serum visfatin levels and its contribution to the developmental process in this disorder.

Methods: Serum visfatin levels were determined by a specific ELISA in 57 SSc patients and 19 healthy controls. The effects of visfatin on the mRNA levels of a2(I) collagen (COL1A2) and matrix metalloproteinase-1 (MMP-1) genes were examined in normal and SSc dermal fibroblasts by reverse-transcript real-time PCR. The levels of IL-12p70 produced by THP-1 cells differentiated with IFN-g plus LPS in the presence or absence of visfatin were measured by a specific ELISA.

Results: Serum visfatin levels were comparable among total SSc, diffuse cutaneous SSc, limited cutaneous SSc, and healthy controls. The only finding in a series of analyses regarding the correlation of serum visfatin levels with clinical symptoms and laboratory data was the significantly longer disease duration in dcSSc with elevated serum visfatin levels than in those with normal levels. Consistently, serum visfatin levels were significantly elevated in late stage dcSSc (disease duration of > 6 years), but not in early and mid-stage dcSSc, compared with healthy controls, suggesting the possible contribution of visfatin to the resolution of skin sclerosis in late stage dcSSc. To assess this hypothesis, two sets of in vitro experiments were carried out using dermal fibroblasts and THP-1 cells. Visfatin suppressed the mRNA levels of COL1A2 gene, while increasing the mRNA levels of MMP-1 gene, in a dose-dependent manner in SSc dermal fibroblasts, whereas the mRNA levels of these genes were not affected by visfatin at all in normal dermal fibroblasts, indicating the direct anti-fibrotic effect of visfatin on SSc dermal fibroblasts. Furthermore, visfatin increased the production of IL-12p70 in THP-1 cells differentiated with IFN-g plus LPS in a dose-dependent manner, suggesting the promotion of Th1 immune responses by visfatin.

Conclusion: Visfatin may contribute to the resolution of skin sclerosis in late stage dcSSc via the direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.


Disclosure:

T. Toyama,
None;

Y. Asano,
None;

Y. Masui,
None;

S. Shibata,
None;

K. Akamata,
None;

S. Noda,
None;

N. Aozasa,
None;

T. Taniguchi,
None;

T. Takahashi,
None;

Y. Ichimura,
None;

H. Sumida,
None;

K. Yanaba,
None;

T. Kadono,
None;

S. Sato,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-possible-contribution-of-visfatin-to-the-resolution-of-skin-sclerosis-in-patients-with-diffuse-cutaneous-systemic-sclerosis-via-a-direct-anti-fibrotic-effect-on-dermal-fibroblasts-and-th1-polarizati/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.